Search

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and debilitating illness with a significant global prevalence, affecting over 65 million individuals. It affects various systems, including the immune, neurological, gastrointestinal, and circulatory systems. Studies have shown abnormalities in immune cell types, increased inflammatory cytokines, and brain abnormalities. Further research is needed to identify consistent biomarkers and develop targeted therapies. This study uses explainable artificial intelligence and machine learning techniques to identify discriminative metabolites for ME/CFS. Material and Methods: The model investigates a metabolomics dataset of CFS patients and healthy controls, including 26 healthy controls and 26 ME/CFS patients aged 22–72. The dataset encapsulated 768 metabolites into nine metabolic super-pathways: amino acids, carbohydrates, cofactors, vitamins, energy, lipids, nucleotides, peptides, and xenobiotics. Random forest methods together with other classifiers were applied to the data to classify individuals as ME/CFS patients and healthy individuals. The classification learning algorithms’ performance in the validation step was evaluated using a variety of methods, including the traditional hold-out validation method, as well as the more modern cross-validation and bootstrap methods. Explainable artificial intelligence approaches were applied to clinically explain the optimum model’s prediction decisions. Results: The metabolomics of C-glycosyltryptophan, oleoylcholine, cortisone, and 3-hydroxydecanoate were determined to be crucial for ME/CFS diagnosis. The random forest model outperformed the other classifiers in ME/CFS prediction using the 1000-iteration bootstrapping method, achieving 98% accuracy, precision, recall, F1 score, 0.01 Brier score, and 99% AUC. According to the obtained results, the bootstrap validation approach demonstrated the highest classification outcomes. Conclusion: The proposed model accurately classifies ME/CFS patients based on the selected biomarker candidate metabolites. It offers a clear interpretation of risk estimation for ME/CFS, aiding physicians in comprehending the significance of key metabolomic features within the model.

Blood cells carry important information that can be used to represent a person’s current state of health. The identification of different types of blood cells in a timely and precise manner is essential to cutting the infection risks that people face on a daily basis. The BCNet is an artificial intelligence (AI)-based deep learning (DL) framework that was proposed based on the capability of transfer learning with a convolutional neural network to rapidly and automatically identify the blood cells in an eight-class identification scenario: Basophil, Eosinophil, Erythroblast, Immature Granulocytes, Lymphocyte, Monocyte, Neutrophil, and Platelet. For the purpose of establishing the dependability and viability of BCNet, exhaustive experiments consisting of five-fold cross-validation tests are carried out. Using the transfer learning strategy, we conducted in-depth comprehensive experiments on the proposed BCNet’s architecture and test it with three optimizers of ADAM, RMSprop (RMSP), and stochastic gradient descent (SGD). Meanwhile, the performance of the proposed BCNet is directly compared using the same dataset with the state-of-the-art deep learning models of DensNet, ResNet, Inception, and MobileNet. When employing the different optimizers, the BCNet framework demonstrated better classification performance with ADAM and RMSP optimizers. The best evaluation performance was achieved using the RMSP optimizer in terms of 98.51% accuracy and 96.24% F1-score. Compared with the baseline model, the BCNet clearly improved the prediction accuracy performance 1.94%, 3.33%, and 1.65% using the optimizers of ADAM, RMSP, and SGD, respectively. The proposed BCNet model outperformed the AI models of DenseNet, ResNet, Inception, and MobileNet in terms of the testing time of a single blood cell image by 10.98, 4.26, 2.03, and 0.21 msec. In comparison to the most recent deep learning models, the BCNet model could be able to generate encouraging outcomes. It is essential for the advancement of healthcare facilities to have such a recognition rate improving the detection performance of the blood cells.

Brain tumors (BTs) are deadly diseases that can strike people of every age, all over the world. Every year, thousands of people die of brain tumors. Brain-related diagnoses require caution, and even the smallest error in diagnosis can have negative repercussions. Medical errors in brain tumor diagnosis are common and frequently result in higher patient mortality rates. Magnetic resonance imaging (MRI) is widely used for tumor evaluation and detection. However, MRI generates large amounts of data, making manual segmentation difficult and laborious work, limiting the use of accurate measurements in clinical practice. As a result, automated and dependable segmentation methods are required. Automatic segmentation and early detection of brain tumors are difficult tasks in computer vision due to their high spatial and structural variability. Therefore, early diagnosis or detection and treatment are critical. Various traditional Machine learning (ML) techniques have been used to detect various types of brain tumors. The main issue with these models is that the features were manually extracted. To address the aforementioned insightful issues, this paper presents a hybrid deep transfer learning (GN-AlexNet) model of BT tri-classification (pituitary, meningioma, and glioma). The proposed model combines GoogleNet architecture with the AlexNet model by removing the five layers of GoogleNet and adding ten layers of the AlexNet model, which extracts features and classifies them automatically. On the same CE-MRI dataset, the proposed model was compared to transfer learning techniques (VGG-16, AlexNet, SqeezNet, ResNet, and MobileNet-V2) and ML/DL. The proposed model outperformed the current methods in terms of accuracy and sensitivity (accuracy of 99.51% and sensitivity of 98.90%).